ProMetic and Serono Sign a Development and Collaboration Agreement

Development revenues for ProMetic of up to £550,000 (approx. $C1.3M)

15-Mar-2004

Montreal, Canada. ProMetic Life Sciences Inc. wholly owned subsidiary ProMetic Biosciences Ltd announced that it has signed a development and collaboration agreement with laboratories Serono S.A. to provide Serono access to ProMetic´s unique protein purification technology.

Serono will fund the development of an affinity adsorbent to isolate and purify a protein of interest to Serono. A Mimetic Ligand(TM) will be selected from ProMetic´s Intelligent Combinatorial Libraries and will be designed to enhance Serono´s already rigorous therapeutic purification procedures.

"We are thrilled that Serono, a world leader in recombinant products, has chosen ProMetic´s technology to further enhance its manufacturing and purification processes!, commented Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. !This agreement confirms once again the establishment of ProMetic as a world leader in the plasma and recombinant protein purification market!.

Other news from the department business & finance

These products might interest you

Systec H-Series

Systec H-Series by Systec

Safe, reproducible and validatable sterilization of liquids, solids and waste

Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

laboratory autoclaves
Whatman™ folded filter papers

Whatman™ folded filter papers by Cytiva

Whatman folded filter papers

Convenient folded formats speed up your sample preparation

filter papers
Loading...

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance